Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (131-140 of 162) with videos related to

Pageof 17
Sort By:
Gut|September 28, 2011
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trialGert Van Assche, Séverine Vermeire, Vera Ballet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2014
Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remissionKonstantinos Papamichael, Niels Vande Casteele, Ann Gils, et al.
Investigative Ophthalmology & Visual Science|May 27, 2003
Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trialsVincent Lambert, Carine Munaut, Peter Carmeliet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Therapeutic Drug Monitoring|June 7, 2014
Development of a universal anti-adalimumab antibody standard for interlaboratory harmonizationAnn Gils, Niels Vande Casteele, Raf Poppe, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 19, 2015
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative ColitisKonstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, et al.
Journal of Crohn'S & Colitis|February 5, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Erwin Dreesen, Maja Noman, et al.
Therapeutic Drug Monitoring|March 1, 2019
Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational StudyAnne-Emmanuelle Berger, Gerard Duru, Annick de Vries, et al.
Planta|November 4, 2010
Advances in understanding pectin methylesterase inhibitor in kiwi fruit: an immunological approachEvelien Vandevenne, Stefanie Christiaens, Sandy Van Buggenhout, et al.
European Journal of Gastroenterology & Hepatology|August 18, 2020
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed labelSebastian Stefanovic, Iris Detrez, Griet Compernolle, et al.
Pageof 17

Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Gut|September 28, 2011
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trialGert Van Assche, Séverine Vermeire, Vera Ballet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2014
Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remissionKonstantinos Papamichael, Niels Vande Casteele, Ann Gils, et al.
Investigative Ophthalmology & Visual Science|May 27, 2003
Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trialsVincent Lambert, Carine Munaut, Peter Carmeliet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Therapeutic Drug Monitoring|June 7, 2014
Development of a universal anti-adalimumab antibody standard for interlaboratory harmonizationAnn Gils, Niels Vande Casteele, Raf Poppe, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 19, 2015
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative ColitisKonstantinos Papamichael, Thomas Van Stappen, Niels Vande Casteele, et al.
Journal of Crohn'S & Colitis|February 5, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Erwin Dreesen, Maja Noman, et al.
Therapeutic Drug Monitoring|March 1, 2019
Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational StudyAnne-Emmanuelle Berger, Gerard Duru, Annick de Vries, et al.
Planta|November 4, 2010
Advances in understanding pectin methylesterase inhibitor in kiwi fruit: an immunological approachEvelien Vandevenne, Stefanie Christiaens, Sandy Van Buggenhout, et al.
European Journal of Gastroenterology & Hepatology|August 18, 2020
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed labelSebastian Stefanovic, Iris Detrez, Griet Compernolle, et al.
Pageof 17